Seung H Lee

This inventor holds 37 USPTO granted patents and 7 published patent applications, plus 8 CIPO patents and 16 EPO patents, primarily in Syk Inhibitors. Top assignees: Gilead Connecticut, Inc., Gilead Sciences, Inc., Genentech, Inc.. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Seung H Lee. Retrieved from https://idiyas.com/inventor/seung-h-lee

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 37 (Patent Applications = 7)

% Patents Active = 81.1

CIPO Patents = 8

EPO Patents = 16 (Patent Applications = 20)

Average Co-Inventor Count = 10.1

ph-index = 13

Forward Citations = 353(Granted Patents)

Location History:

Branford, CT (US) (2010 - 2019)
Sammamish, WA (US) (2017 - 2024)

Company Filing History:

15 out of 30

Gilead Connecticut, Inc.

patents

14 out of 946

Gilead Sciences, Inc.

Cgi Pharmaceuticals, Inc.

Ono Pharmaceutical Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2010-2025

Loading Chart...

Areas of Expertise:

Syk Inhibitors

Crystalline Compounds

Substituted Azabenzimidazoles

Imidazopyridines

Pyridone Compounds

Bruton's Tyrosine Kinase

Pyrazolo Compounds

Aza-Pyridone Compounds

Substituted Amides

Imidazopyrazines

Imidazopyrimidines

Substituted Pyrazinones

37 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12459922 - PARP7 inhibitors (2025-11-04),

2. 12263163 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor (2025-04-01),

3. 12258346 - Substituted 6-azabenzimidazole compounds (2025-03-25),

4. 11925631 - Substituted 6-azabenzimidazole compounds (2024-03-12),

5. 11897878 - Substituted 6-azabenzimidazole compounds (2024-02-13),

6. 11517570 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine (2022-12-06),

7. 11203591 - Substituted 6-azabenzimidazole compounds (2021-12-21),

8. 11071730 - Substituted 6-azabenzimidazole compounds (2021-07-27),

9. 10842803 - Imidazopyridines Syk inhibitors (2020-11-24),

10. 10828299 - Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine (2020-11-10),

11. 10344040 - Pyridone and aza-pyridone compounds and methods of use (2019-07-09),

12. 10342794 - Substituted imidazo[1,2-a]pyrazines as Syk inhibitors (2019-07-09),

13. 10314844 - Inhibitors of Bruton's tyrosine kinase (2019-06-11),

14. 10093684 - Substituted imidazo[1,2-a]pyrazines as Syk inhibitors (2018-10-09),

15. 10092583 - Imidazopyridines Syk inhibitors (2018-10-09),

Title: The Innovative Contributions of Seung H Lee in the Field of Pharmaceuticals

Introduction: Seung H Lee is a prominent inventor based in Branford, CT, known for his significant contributions to pharmaceutical innovations. With a remarkable portfolio of 34 patents, Lee has pioneered the development of novel compounds aimed at addressing various diseases, including viral infections and cancers.

Latest Patents: Among his latest innovations are the substituted 6-azabenzimidazole compounds. These compounds are integral to pharmaceutical compositions designed to treat or prevent diseases and disorders that can be modified by hematopoietic progenitor kinase 1 (HPK1) inhibitors. Notable conditions targeted by these compounds include Hepatitis B Virus (HBV), Human Immunodeficiency Virus (HIV), cancer, and other hyper-proliferative diseases. The methodologies surrounding these compounds showcase Lee's commitment to advancing therapeutic options for complex health issues.

Career Highlights: Seung H Lee has had a notable career trajectory, having worked with prestigious organizations such as Gilead Connecticut, Inc. and Gilead Sciences, Inc. His experience in these companies has not only contributed to his expertise in pharmaceutical development but also to the proliferation of innovative treatment approaches in the industry.

Collaborations: Throughout his career, Lee has collaborated with esteemed colleagues including Scott A Mitchell and Kevin S Currie. These partnerships have undoubtedly fostered a collaborative environment that encourages the exchange of ideas and enhances the creative process behind developing successful pharmaceutical innovations.

Conclusion: Seung H Lee's innovations highlight the vital role of inventors in the pharmaceutical sector. His contributions through his numerous patents, particularly in the development of substituted 6-azabenzimidazole compounds, demonstrate an impactful commitment to addressing some of the most pressing health concerns today. With a solid foundation in collaboration and a passion for research, Lee continues to pave the way for future advancements in medical treatments.

Profile summary based on public USPTO records.